Cerebral vasospasm is the classic cause of delayed neurological deterioration after subarachnoid hemorrhage (SAH). Surprisingly, however, patient outcome after SAH was not improved in recent trials of the endothelin antagonist clazosentan, which prevents vasospasm. In light of this result, Macdonald et al. highlight the need for reconsideration of the pathophysiology of SAH.
- R Loch Macdonald
- Ryszard M Pluta
- John H Zhang
